ea0098t10 | Trials In Progress | NANETS2023
F Kennecke MD, MHA, FRCPC Hagen
, Yamasaki, RN Lena
, Kasi, MD, MPH Anup
, Herz Katherine
, Mittra MD Erik S.
Background: Combination peptide receptor radionuclide therapy (PRRT) with the multikinase inhibitor cabozantinib may result in enhanced tumor response and improved intratumoral delivery of Lu-177 DOTATATE by normalization of tumor vasculature through VEGFR inhibition.Methods: In a phase Ib trial, patients with advanced somatostatin receptor (SSTR) positive, G1-3 neuroendocrine tumors (NETs) with a Krenning score of >2 are treated with 4 x 8 week cycl...